Altamira Therapeutics Ltd Aktie News

Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA / May 1, 2024 / Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it has filed a provisional patent application with the United States Patent Office (USPTO) which covers nanopa...

Hamilton, Bermuda, April 24, 2024 (GLOBE NEWSWIRE) -- HAMIL TON, BERMUDA -- April 24 , 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the publication of the detailed results from the NASAR clinical trial with Bentrio® nasal spray in seasona...

Altamira Therapeutics Ltd. (NASDAQ:CYTO ) Q4 2023 Earnings Conference Call April 10, 2024 8:30 AM ET Company Participants Thomas Meyer - Founder, Chairman & Chief Executive Officer Covadonga Pañeda - Chief Operating Officer Operator Good morning, and welcome to the Altamira Therapeutics Business Update and Full Year 2023 Earnings Conference Call.

Hamilton, Bermuda, April 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its Full Year 2023 Financial Results and Business Update Call on Friday, April 10, 2024. Founder, Chairman, and CEO Thomas Meyer and C...

HAMILTON, BERMUDA, March 25, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it has entered into a collaboration agreement with Univercells Group (“Univercells”) to evaluate the use of the Company's proprietary SemaPhore plat...

HAMILTON, BERMUDA, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Independent peer-reviewed study shows enhanced cell transduction with adeno-associated virus (AAV) vectors, commonly used in gene therapy, when integrating Altamira's peptide-based delivery technology      Increased potency may help to reduce AAV immunogenicity and resistance to AAVs in certain cell types  HAMILTON, BERMUDA, Feb. 7, 2024 -- A...

HAMILTON, BERMUDA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA, Jan. 24, 2024 -- Altamira Therapeutics Ltd. (Nasdaq: CYTO) ("Altamira" or the "Company"), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it has filed a second provisional patent application with the United States Patent and Trade Office (USPTO) to p...

HAMILTON, BERMUDA , Jan. 08, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit